News & Media

Industry news curated and delivered to inform your dealmaking strategies. We select the most relevant information, providing a consistent, convenient source for exclusive intelligence and analysis.

Page 4

Mergers & Acquisitions

Drinks With The Deal: Sullivan & Cromwell’s Frank Aquila

By David Marcus
|
Published: January 10th, 2020
Sullivan’s head of M&A talks to The Deal's David Marcus about his recent work for Tiffany’s, Novartis and Amgen, the challenges consumer goods companies face, and his favorite bars in Hong Kong, Tokyo and New York.
Mergers & Acquisitions

Yum Snags Habit Burger Grill

By Alexandra Garfinkle
|
Published: January 6th, 2020
Taco Bell and KFC operator Yum! Brands acquires fast-casual burger chain Habit Burger Grill, which has been on The Deal's Watch List since June, for $375 million in cash.
Activism

Brookfield Takes Cincinnati Bell Private

By Chris Nolter
|
Published: December 24th, 2019
Expanding its telecom portfolio, Brookfield Infrastructure Partners is buying Mario Gabelli-targted phone, broadband and video service provider Cincinnati Bell for $2.6 billion.
Mergers & Acquisitions

DraftKings Hits Public Market With SPAC Merger

By Michael Brown
|
Published: December 24th, 2019
The daily fantasy and sports betting company has agreed to a merger with special purpose acquisition company Diamond Eagle Acquisition.
Mergers & Acquisitions

Rubicon, Telaria to Form Ad-Selling Powerhouse

By Chris Nolter
|
Published: December 19th, 2019
The two ad tech companies announce a merger to gain clout in video and digital advertising landscape that includes Google, Amazon and Facebook.
Mergers & Acquisitions

Post-Merger T-Mobile Won’t Be Maverick: States’ Expert

By Chris Nolter
|
Published: December 12th, 2019
An expert witness for the group of states suing to block T-Mobile's purchase of Sprint testified Wednesday that the post-merger company would likely lose its zeal for aggressive price competition.
Mergers & Acquisitions

Merck Expands Oncology Pipeline With ArQule

By Armie Margaret Lee
|
Published: December 9th, 2019
The biopharmaceutical giant is paying a 107% premium for the target, which focuses on therapies for treating cancer and rare diseases.